Lawsuits from around the country over alleged contamination in blood pressure and heart disease drug Valsartan are being transferred to a federal judge in Camden following a consolidation order by the Judicial Panel on Multidistrict Litigation.
The suits were granted mass tort status after an investigation by the Food and Drug Administration found that Valsartan contained trace amounts of N-nitrosodimethylamine, also known as NDMA, a probable human carcinogen. The tainted drugs in question were made in a facility in China and sold as generics in the U.S.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
